Suffix-based naming conventions for biosimilars outlined in draft guidance by the US Food and Drug Administration should be abandoned, the Federal Trade Commission has urged in comments submitted to the agency.
Earlier this year, the FDA released updated draft guidance on naming conventions for biologics and biosimilars that reinforced its commitment...





